MedTrace Logo

Multicenter Phase I Study of HRS-6208 in Patients With Solid Tumors

NCT06727812 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 206

Last updated 2025-12-18

No results posted yet for this study

Summary

This is an open, multicenter Phase I study to evaluate the safety and tolerability of HRS-6208 in patients with advanced solid tumors.

Conditions

Interventions

DRUG

HRS-6208

HRS-6208.

Sponsors & Collaborators

  • Shandong Suncadia Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-17
Primary Completion
2027-08-31
Completion
2027-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06727812 on ClinicalTrials.gov